Prognostic Significance of Immune-checkpoint Molecule PD-L1 in
Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120
Cases

J 2023

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, Jozef MICHALKA, Jan MUŽÍK et. al.

Basic information

Original name

Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases

Authors

KUBEŠ, Václav (203 Czech Republic, belonging to the institution), Leoš KŘEN (203 Czech Republic, belonging to the institution), Filip SOKOL (203 Czech Republic, belonging to the institution), Jozef MICHALKA (703 Slovakia, belonging to the institution), Jan MUŽÍK (203 Czech Republic, belonging to the institution), Tomáš ARPÁŠ (703 Slovakia, belonging to the institution), Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution) and Zdeněk KRÁL (203 Czech Republic, guarantor, belonging to the institution)

Edition

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2023, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.300 in 2022

RIV identification code

RIV/00216224:14110/23:00131588

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/invivo.13261

UT WoS

001024840700028

Keywords in English

Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse

Abstract

V originále

Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.

Links

MUNI/A/1395/2022, interní kód MU

Name: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“

Investor: Masaryk University

Citovat

KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, Jozef MICHALKA, Jan MUŽÍK, Tomáš ARPÁŠ, Zdenka KŘENOVÁ and Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2023, vol. 37, No 4, p. 1735-1742. ISSN 0258-851X. Available from: https://dx.doi.org/10.21873/invivo.13261.

@article{2306558,
   author = {Kubeš, Václav and Křen, Leoš and Sokol, Filip and Michalka, Jozef and Mužík, Jan and Arpáš, Tomáš and Křenová, Zdenka and Král, Zdeněk},
   article_location = {ATHENS},
   article_number = {4},
   doi = {http://dx.doi.org/10.21873/invivo.13261},
   keywords = {Classic Hodgkin lymphoma; PD-L1 expression; treatment; overall survival; relapse},
   language = {eng},
   issn = {0258-851X},
   journal = {In vivo},
   title = {Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases},
   url = {https://iv.iiarjournals.org/content/37/4/1735},
   volume = {37},
   year = {2023}
}

TY  - JOUR
ID  - 2306558
AU  - Kubeš, Václav - Křen, Leoš - Sokol, Filip - Michalka, Jozef - Mužík, Jan - Arpáš, Tomáš - Křenová, Zdenka - Král, Zdeněk
PY  - 2023
TI  - Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases
JF  - In vivo
VL  - 37
IS  - 4
SP  - 1735-1742
EP  - 1735-1742
PB  - Greece : International Institute of Anticancer Research
SN  - 0258851X
KW  - Classic Hodgkin lymphoma
KW  - PD-L1 expression
KW  - treatment
KW  - overall survival
KW  - relapse
UR  - https://iv.iiarjournals.org/content/37/4/1735
N2  - Background/Aim: Classic Hodgkin lymphoma (cHL) is a common B-cell malignancy. Despite the good prognosis, in some patients the standard chemotherapy and radiotherapy-based approach does not lead to long-term remission, and these patients eventually relapse. Moreover, the primary refractory disease is of major concern regarding prognosis. Patients and Methods: We performed a retrospective analysis to evaluate PD-L1 expression in 120 patients with classic Hodgkin lymphoma (cHL). Results: The median follow-up of the entire group of patients was 90 months. After initial therapy, complete remission was achieved in 113 (94.2%) patients. During the follow-up, cHL relapse/refractory disease was reported in 23 (19.2%) cases. A total of five patients died during the follow-up period, all from cHL progression. When determining PD-L1 expression on Hodgkin-Reed-Sternberg (HRS) cells, 37 cases (30.8%) were evaluated as negative, and 83 cases (69.2%) as positive. In the negative PD-L1 group of patients, no cHL relapse/refractory disease was observed during the follow -up period. However, out of 83 patients with positive PD-L1 expression on HRS cells, 23 (28%) showed relapse/refractory cHL. Conclusion: A significantly higher relapse rate was observed in PD-L1-positive patients diagnosed with cHL.
ER  -

KUBEŠ, Václav, Leoš KŘEN, Filip SOKOL, Jozef MICHALKA, Jan MUŽÍK, Tomáš ARPÁŠ, Zdenka KŘENOVÁ and Zdeněk KRÁL. Prognostic Significance of Immune-checkpoint Molecule PD-L1 in Classical Hodgkin Lymphoma: A Clinicopathologic Study of 120 Cases. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2023, vol.~37, No~4, p.~1735-1742. ISSN~0258-851X. Available from: https://dx.doi.org/10.21873/invivo.13261.

Detailed Information on Publication Record